TY  - GEN
AU  - Bartlett,Nancy L
AU  - Smith,Mitchell R
AU  - Siddiqi,Tanya
AU  - Advani,Ranjana H
AU  - O'Connor,Owen A
AU  - Sharman,Jeff P
AU  - Feldman,Tatyana
AU  - Savage,Kerry J
AU  - Shustov,Andrei R
AU  - Diefenbach,Catherine S
AU  - Oki,Yasuhiro
AU  - Palanca-Wessels,Maria Corinna
AU  - Uttarwar,Mayur
AU  - Li,Martha
AU  - Yang,Jing
AU  - Jacobsen,Eric D
TI  - Brentuximab vedotin activity in diffuse large B-cell lymphoma with CD30 undetectable by visual assessment of conventional immunohistochemistry
SN  - 1029-2403
PY  - 2018///0112
KW  - Adult
KW  - Aged
KW  - Aged, 80 and over
KW  - Antineoplastic Agents, Immunological
KW  - administration & dosage
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - adverse effects
KW  - Biomarkers
KW  - Brentuximab Vedotin
KW  - Drug Resistance, Neoplasm
KW  - Female
KW  - Humans
KW  - Immunoconjugates
KW  - Immunohistochemistry
KW  - Ki-1 Antigen
KW  - metabolism
KW  - Lymphoma, Large B-Cell, Diffuse
KW  - diagnosis
KW  - Male
KW  - Middle Aged
KW  - Neoplasm Staging
KW  - Recurrence
KW  - Retreatment
KW  - Treatment Outcome
KW  - Young Adult
N1  - Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study
UR  - https://doi.org/10.1080/10428194.2016.1256481
ER  -